Breast Cancer Trial, Recruiting NCT06629896 Sponsor: Azienda USL Reggio Emilia - IRCCS Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06629896
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women aged between 35 and 60 years who are considered at high risk of developing breast cancer, either already being cared for at a participating centre or referred through an early diagnosis programme
  • Women whose estimated risk of developing breast cancer in the next 5 years is 5% or higher, as calculated using one of several accepted risk assessment tools (confirm with trial site which tool applies)
  • Women whose 10-year breast cancer risk is assessed as greater than 10% using recognised risk calculation models such as Tyrer-Cuzick IBIS, BOADICEA, or BCSC
  • Women who previously took part in the MyPeBS study and were classified as very high risk, and who have finished the active follow-up period of that study
  • Women who have previously had radiation therapy directed at the chest area

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a previous diagnosis of breast cancer
  • People who are currently pregnant
  • People who have had both breasts surgically removed (bilateral mastectomy)
  • People with psychiatric or other conditions that may make it difficult to follow the trial's requirements and attend follow-up appointments
  • People who are not willing or able to remain in the trial for at least 2.5 years
  • People who are unable to understand the trial information or to give or decline informed consent freely

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39335499770

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda USL Reggio Emilia - IRCCS
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
7 July 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Cumulative incidence of BC; Cumulative recall rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov